Lakewood-Amedex Biotherapeutics Inc. (LABT) Stock

Understand Lakewood-Amedex Biotherapeutics Inc.: how it makes money

Lakewood-Amedex Biotherapeutics Inc. is a healthcare company focused on pharmaceutical products. The provided information does not specify exactly how it makes money (for example, product sales versus services).

In the latest quarter, the company reported deeply negative gross and operating margins, indicating the profit model is not currently covering costs from the reported revenue base.

Business quality (Weak): Data limitations are significant (no segment breakdown and no operating KPIs provided). The only clear signal is that the latest quarter shows very large negative gross and operating margins, which is a major risk to the business model until economics improve.

Bull case

• Clear margin gap to close: Because both gross margin and operating margin are reported as deeply negative, any improvement in product economics and cost structure would likely be a key swing factor for results.

Bear case

• Loss-making in the latest quarter: For the period ended 2026-03-31, gross margin and operating margin are both reported as sharply negative, and revenue is shown as 0.0B in the provided facts.
• Limited visibility on drivers: No official reportable segments and no operational KPIs were provided, making it harder for investors to track what specifically is driving performance.

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Bolt Biotherapeutics, Inc. (BOLT)
• Acurx Pharmaceuticals, Inc. (ACXP)
• Dermata Therapeutics, Inc. (DRMA)
• Cadrenal Therapeutics, Inc. Common Stock (CVKD)
• Pulmatrix, Inc. (PULM)
• Aptevo Therapeutics Inc. (APVO)
• Revelation Biosciences, Inc. (REVB)
• FibroBiologics, Inc. Common Stock (FBLG)